---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000153"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:26:46.599952+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas Q3 net loss narrows to $25.1M; preclinical EDIT-401 shows >90% LDL-C reduction; cash runway extended to Q3 2027

## Summary
- Net loss of $25.1M ($0.28/sh) vs $62.1M ($0.75/sh) in Q3 2024; collaboration revenue rose to $7.5M from $0.1M on BMS milestone.
- R&D expenses fell 58% to $19.8M; G&A expenses fell 32% to $12.3M, both reflecting reni-cel program discontinuation.
- Cash & securities $165.6M at Sept. 30; $17.8M raised via ATM in Q3; runway extended into Q3 2027, enabling EDIT-401 progression.
- Preclinical data: single dose of EDIT-401 achieved ≥90% LDL-C reduction in NHPs within 48 hours; durability shown in 3-month mouse study.
- On track to file IND/CTA for EDIT-401 by mid-2026; initial human proof-of-concept data expected by year-end 2026.

## SEC filing metadata
- accession: 0001650664-25-000153
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/0001650664-25-000153-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/edit-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000153
- JSON: https://secwatch.observer/filing/0001650664-25-000153.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000153.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.